Astellas Pharma Gmbh

Fujisawa Pharmaceutical Company, Ltd.

Kenichiro Imamura

Kazuhiko Ohne

Yuki Sawada

Naoki Ishibashi

Makoto Inoue

Yoshito Abe

Kentaro Sato

Kozo Sawada

Takehiko Ohkawa

Tsuyoshi Mizutani

Ichiro Shima

Mitsuaki Okumura

Hiroshi Shibata

Hiroyuki Moritomo

Kazuhiro Yokoyama

Yuji Koga

Kenichi Onda

Tsubasa Watanabe

Ippei Sato

Kyoichi Maeno

Keita Nakanishi

Yoshimasa Imamura

Eisuke Nozawa

Yasuharu Urano

Takeshi Hanazawa

Maiko Iida

Fumie Sato

Shigetada Furukawa

Kazuhiro Momose

An excellent drug for treating or preventing cardiovascular diseases, based on cGMP production enhancing action due to soluble guanylate cyclase activating action, is provided. It was found that imidazopyridine compounds having a carbamoyl group at the 3-position and a substituent bonded at the 8-position via an oxygen atom in an imidazo[1,2-a]pyridine skeleton exhibits a cGMP production enhancing action by a potent soluble guanylate cyclase activating action, and is useful as a drug for treating or preventing various soluble guanylate cyclase-related cardiovascular diseases, thereby completing the present invention.

Imidazopyridine compounds

As a result of extensive studies on NAD(P)H oxidase inhibitors, the present inventors found that a quinolone derivative having, at the 2-position, an alkyl group substituted with a heteroatom or the like has an excellent NAD(P)H oxidase inhibitory activity, and accomplished the present invention. The compound of the present invention has a reactive oxygen species production inhibitory activity based on the NAD(P)H oxidase inhibitory activity, and therefore can be used as an agent for preventing and/or treating diabetes, impaired glucose tolerance, hyperlipidemia, fatty liver, diabetic complications and the like.

Quinolone derivative

The invention relates to compound of the formula (I) or its salt, in which R, R, Rand Rare as defined in the description, their use of as medicament, the process for their preparation and use for the treatment of PDE-IV or TNF-&#x3b1; mediated diseases 

Pyrrolopyridazine derivatives

The present invention relates to a compound of the formula (I) wherein R1 is benzofuranyl substituted by halogen, or styryl substituted by halogen; R2 is substituted hydroxy, substituted mercapto or substituted sulfonyl; and X is or pharmaceutically acceptable salts thereof. The compound (1) of the present invention and pharmaceutically acceptable salts thereof possess a strong inhibitory activity on the production of nitric oxide (NO), and are useful for prevention and/or treatment of NO-mediated diseases in human being and animals 

Peptide compounds

Substituted dipeptides having nos inhibiting activity

Growing community of inventors

Osaka, Japan

Kenichiro Imamura